Merus to Participate in a Panel Discussion at Citi’s 17th Annual BioPharma Conference

On September 1, 2022 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET (Press release, Merus, SEP 1, 2022, View Source [SID1234618905]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the panel discussion will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.